期刊文献+
共找到256篇文章
< 1 2 13 >
每页显示 20 50 100
Prognosis of Connective Tissue Disease Related Interstitial Lung Disease after Initiation of Long-Term Oxygen Therapy: Comparison with Idiopathic Pulmonary Fibrosis
1
作者 Mayuko Ishiwari Yuta Kono +4 位作者 Yuki Togashi Kenichi Kobayashi Ryota Kikuchi Mariko Kogami Shinji Abe 《Open Journal of Respiratory Diseases》 2024年第4期111-121,共11页
Objective: The studies of long-term oxygen therapy (LTOT) for patents with connective tissue disease-related interstitial lung disease (CTD-ILD) are limited. This study aimed to evaluate the prognosis of CTD-ILD patie... Objective: The studies of long-term oxygen therapy (LTOT) for patents with connective tissue disease-related interstitial lung disease (CTD-ILD) are limited. This study aimed to evaluate the prognosis of CTD-ILD patients following the initiation of LTOT, compared to those with idiopathic pulmonary fibrosis (IPF). Methods: We conducted a retrospective analysis of patients with CTD-ILD and IPF who were introduced to LTOT between January 2014 and December 2020. Results: The study included 24 patients with CTD-ILD and 55 patients with IPF. At the initiation of LTOT, female gender, never-smoking history, higher body mass index (BMI), higher lactate dehydrogenase (LDH) level, lower pulmonary Surfactant Protein-D (SP-D) level and lower Gender-Age-Physiology (GAP) scores were more common in the CTD-ILD group (all Conclusion: Although patients with CTD-ILD had longer overall survival than those with IPF, there was no significant difference in prognosis after the initiation of LTOT between the two groups. Early intervention including treatment and management will be needed in CTD-ILD as in IPF. 展开更多
关键词 CTD-ILD idiopathic pulmonary fibrosis IPF Long-Term Oxygen therapy LTOT
下载PDF
Integrated bioinformatics analysis of key candidate genes and therapeutic drugs for idiopathic pulmonary fibrosis
2
作者 Tong-Tong Zhang Jia-Yu Zhang +6 位作者 Yu Li Chang-Wen Zhang Wen-Tao Li Ming-Peng Xu Cai-Zhen Yang Yin-Kang Li Guang-Nan Liu 《Asian Toxicology Research》 2020年第4期151-164,共14页
Background: Idiopathic pulmonary fibrosis is a form of fibrotic and fatal lung disease worldwide with unknownetiology and mechanisms. This manuscript focused on clarifying the core protein-protein interaction network,... Background: Idiopathic pulmonary fibrosis is a form of fibrotic and fatal lung disease worldwide with unknownetiology and mechanisms. This manuscript focused on clarifying the core protein-protein interaction network, genesand related pathways correlated with idiopathic pulmonary fibrosis in detail. Methods: Gene chip (GSE24206) wasacquired from the Gene Expression Omnibus database. GEO2R was a R-based online tool to screen differentialexpressed genes. Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes analysis were utilized toascertain gene function and key signaling pathways. The Search Tool for the Retrieval of Interacting Genes was usedto construct the protein-protein interaction network. Key genes and module analysis were screened out usingCytohubba and MCODE plugin. The candidate therapeutic molecular drugs were searched for IPF using DGIdbdatabase. Results: A cohort of 240 differential expression of genes (113 up-regulated and 127 down-regulated) wereknocked out. Gene Ontology enrichment analysis indicated that some differential expression of genes were involvedin extracellular matrix and neutrophil chemotaxis. The Kyoto Encyclopedia of Genes and Genomes pathways werepredominantly involved in chemokine signaling pathway and ECM-receptor interactions. Two significant modulesand 5 hub genes were strongly implicated in idiopathic pulmonary fibrosis from protein-protein interaction network.The 2 module genes were primarily enriched in the cytokine-cytokine receptor, TNF signaling pathway, toll-likesignaling pathway, and Wnt signaling pathway. Finally, 41 small molecules were identified by DGIdb database as thepotential drugs of idiopathic pulmonary fibrosis. Conclusion: To conclude, in this study, the hub genes, signalingpathways, and small molecules will conduce to better understanding the mechanisms and may provide new methodsto the therapy of idiopathic pulmonary fibrosis. 展开更多
关键词 idiopathic pulmonary fibrosis Bioinformatics analysis Differentially expressed genes Molecular targeted therapy
下载PDF
Research progress of Chinese medicine in treatment of IPF(idiopathic pulmonary fibrosis)
3
作者 Luo Haili Cai Lingling +5 位作者 Sun Song Cao Ting WU Meichao Wu Zhisong Fan Maorong Wang Shuchen 《World Journal of Integrated Traditional and Western Medicine》 2017年第2期18-21,共4页
Idiopathic pulmonary interstitial fibrosis is one of the respiratory refractory diseases,and the incidence rate is on the rise.At present,the effect of western medicine is not ideal and the side effects are obvious,wh... Idiopathic pulmonary interstitial fibrosis is one of the respiratory refractory diseases,and the incidence rate is on the rise.At present,the effect of western medicine is not ideal and the side effects are obvious,while the traditional Chinese medicine shows good curative effect on the disease.This paper makes a summary on the traditional Chinese medicine theory in treating idiopathic pulmonary interstitial fibrosis in recent years. 展开更多
关键词 idiopathic pulmonary interstitial fibrosis Chinese medicine Research progress
下载PDF
The Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Idiopathic Interstitisal Pneumonia
4
作者 Ji Young Shin Yu Jin Kim +2 位作者 Sun Young Kyung Seung Yeon Ha Sung Hwan Jeong 《Open Journal of Respiratory Diseases》 2014年第3期101-109,共9页
Background: Idiopathic interstitial pneumonia is characterized by fibroblast proliferation and extracellular matrix (ECM) accumulation. Matrix metalloproteases (MMPs) and tissue inhibitors of metalloproteases (TIMPs) ... Background: Idiopathic interstitial pneumonia is characterized by fibroblast proliferation and extracellular matrix (ECM) accumulation. Matrix metalloproteases (MMPs) and tissue inhibitors of metalloproteases (TIMPs) have been shown to regulate remodeling of the ECM, which indicates that they are important factors in the process of lung fibrosis. Therefore, we evaluated the expression of MMPs and TIMPs in tissues obtained from patients with idiopathic interstitial pneumonia and control tissues. Methods: Thirty-seven patients who were diagnosed with IIP (22: IPF, 13: NSIP, 2: COP) and 5 controls were enrolled in this study. The MMP-2 and -9 activity in lung tissue obtained from these patients was analyzed using gelatin zymography and the levels of TIMP-1 and -2 were measured by western blotting. We also evaluated the expression of MMP-2 and -9, as well as that of TIMP-1 and -2 in lung tissue using immunohistochemistry. Results: The levels of MMP-2 and MMP-9 were significantly increased in patients with IPF compared to those with NSIP and COP. The activities of TIMP-1 and -2 were also higher in patients with IPF than NSIP/COP patients and control subjects. There were no significant differences observed in the activities of MMPs and TIMPs obtained from patients with NSIP/COP and control subjects. The immunohistochemical analysis showed that TIMP-2 and MMP-2 were strongly stained at the fibroblasts of the fibroblastic foci in patients with IPF. Conclusions: These results suggest that over-expression of gelatinases and TIMPs in patients with IPF are important factors in the irreversible fibrosis that is associated with lung parenchyma. 展开更多
关键词 idiopathic interstitial PNEUMONIA idiopathic pulmonary fibrosis Matrix METALLOPROTEINASES Tissue Inhibitor of Matalloproteinases NONSPECIFIC interstitial PNEUMONIA CRYPTOGENIC Organizing PNEUMONIA
下载PDF
Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs.possible usual interstitial pneumonitis pattern
5
作者 Meng-Shu Cao Jian Sheng +5 位作者 Tian-Zhen Wang Xiao-Hua Qiu Dong-Mei Wang Yang Wang Yong-Long Xiao Hou-Rong Cai 《Chinese Medical Journal》 SCIE CAS CSCD 2019年第18期2177-2184,共8页
Background:The prognosis of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is very poor with a high mortality.The aim of this study was to describe the clinical features and survival of patients with AE-... Background:The prognosis of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is very poor with a high mortality.The aim of this study was to describe the clinical features and survival of patients with AE-IPF with usual pulmonary fibrosis (UIP) and possible UIP (P-UIP) pattern on chest high resolution computed tomography (HRCT).Methods:This retrospective study included 107 patients with AE-IPF admitted to Nanjing Drum Tower Hospital from January 2010 to December 2016.The subjects were divided into UIP (n =86) and P-UIP group (n=21) based on chest HRCT.Continuous variables were analyzed using Student's t test or Mann-Whimey U test.Categorical variables were analyzed using x2 test.Log-rank test was used for the survival analysis.Cox proportional models evaluated the risk factors for AE occurrence and survival.Results:The male,older patients,previous N-acetylcysteine use,elevated white blood cell (WBC) counts,and microbiology infection were more common in the UIP group than the P-UIP group (X2 =13.567,P < 0.001;z =-2.936,P =0.003;X2 =5.901,P =0.015;t =2.048,P =0.043;x2 =10.297,P =0.036,respectively).The percentage of AE with UIP pattern in idiopathic interstitial pneumonia (ⅡP) was significantly higher than P-UIP pattern (X2 =40.011,P < 0.001).Smoking was the risk factor for AE within 6 months after IPF diagnosis in the UIP group.The cumulative proportion survival of 30-days was significantly higher in the UIP group compared with the P-UIP group (x2 =5.489,P =0.019) despite of the similar overall survival in the two groups.Multivariate Cox regression analysis indicated WBC count,partial pressure of oxygen in artery (PaO2)/ffactional concentration of inspired oxygen (FiOz),and computed tomography (CT) score were the independent predictors for survival in the UIP group (hazard ratio [HR]:1.070,95% confidential interval [CI]:1.027-1.114,P=0.001;HR:0.992,95% CI:0.986-0.997,P=0.002;and HR:1.649,95% CI:1.253-2.171,P < 0.001,respectively).Conclusions:AE occurrence of UIP patients in IIP was significantly more than P-UIP cases.The short-term survival was better in the UIP group despite of the similar overall survival in the two groups.WBC count,PaO2/FiO2,and CT score were the independent predictors for survival in UIP subjects. 展开更多
关键词 idiopathic pulmonary fibrosis Acute EXACERBATION Usual interstitial PNEUMONITIS
原文传递
Interstitial lung disease and diabetes 被引量:10
6
作者 Venkat Rajasurya Kulothungan Gunasekaran Salim Surani 《World Journal of Diabetes》 SCIE CAS 2020年第8期351-357,共7页
Diabetes mellitus (DM) is a chronic metabolic disease and its prevalence has beensteadily increasing all over the world. DM and its associated micro andmacrovascular complications result in significant morbidity and m... Diabetes mellitus (DM) is a chronic metabolic disease and its prevalence has beensteadily increasing all over the world. DM and its associated micro andmacrovascular complications result in significant morbidity and mortality. Themicrovascular complications are usually manifested as retinopathy, neuropathy,nephropathy and macrovascular complications generally affect the cardiovascularsystem. In addition to these complications, DM also affects the lungs because of itsrich vascularity and abundance in connective tissue (collagen and elastin). DMhas been found to cause microvascular complications and proliferation ofextracellular connective tissue in the lungs, leading to decline in lung function in arestrictive pattern. Interstitial lung disease (ILD) includes a diverse group ofdisease conditions characterized by different degrees of inflammation and fibrosisin the pulmonary parenchyma. Idiopathic pulmonary fibrosis (IPF) is one of thecommon type of idiopathic interstitial pneumonia with a high mortality rate. IPFis characterized by chronic progressive fibrosis leading to progressive respiratoryfailure. In this review we focus on lung as the target organ in DM and theassociation of DM and ILD with special emphasis on IPF. 展开更多
关键词 Diabetes mellitus interstitial lung disease idiopathic pulmonary fibrosis METFORMIN Diabetes complications pulmonary function test Restrictive lung disease HYPERGLYCEMIA
下载PDF
Polymyxin B-immobilized fiber columns:A column to breathe new life into the treatment of interstitial lung disease? 被引量:2
7
作者 Katsuaki Asakawa Toshinori Takada 《World Journal of Respirology》 2015年第1期1-3,共3页
Acute exacerbations of idiopathic pulmonary fibrosis(IPF) is a severe respiratory condition with high mortality rate. Direct hemoperfusion with polymyxin B-immobilized fiber columns(PMX-DHP) was originally introduced ... Acute exacerbations of idiopathic pulmonary fibrosis(IPF) is a severe respiratory condition with high mortality rate. Direct hemoperfusion with polymyxin B-immobilized fiber columns(PMX-DHP) was originally introduced for the treatment of septic shock. Application of PMX-DHP to the treatment of acute exacerbations of IPF may improve oxygenation and survival of the patients with the disease. In addition to acute exacerbations of IPF, PMXDHP has been applied to acute respiratory failure fromvarious causes; an amyopathic dermatomyositis patient who developed rapidly progressive interstitial lung disease(ILD) with elevated anti-CADM-140/MDA5 autoantibody and a patient with severe amiodarone pulmonary toxicity. It is also demonstrated that PMX-DHP performed on the first day of steroid pulse therapy may improve the prognosis of patients with rapidly progressive ILDs in a case-control setting. PMX treatment decreases not only various circulating molecules but also inflammatory cells, in particular activated monocytes, producing such mediators. Although the incidence of acute exacerbations of IPF is too low for proper randomization, in order to test the effects of PMX-DHP on the disease, a cohort or casecontrol analytic study needs to be conducted, preferably from more than one center or research group. 展开更多
关键词 Acute EXACERBATION idiopathic pulmonary fibrosis POLYMYXIN B HEMOPERFUSION interstitial lung disease
下载PDF
中医药治疗特发性肺纤维化研究进展 被引量:1
8
作者 张晓磊 郭思佳 《光明中医》 2024年第7期1457-1458,F0003,F0004,共4页
特发性肺纤维化是原因不明的慢性进行性致纤维化间质性肺炎,主要见于中老年男性,局限于肺,临床上呈渐进性呼吸困难和肺功能恶化,组织病理学和胸部HRCT表现为特征性的寻常型间质性肺炎。特发性肺纤维化属中医学“肺痿、肺痹”范畴,中医... 特发性肺纤维化是原因不明的慢性进行性致纤维化间质性肺炎,主要见于中老年男性,局限于肺,临床上呈渐进性呼吸困难和肺功能恶化,组织病理学和胸部HRCT表现为特征性的寻常型间质性肺炎。特发性肺纤维化属中医学“肺痿、肺痹”范畴,中医对此病的认识历史悠久,优势明显,近年来受到越来越多的重视,通过对近5年多(2018年—至今)中医药在特发性肺纤维化的研究文献进行总结,主要从病机(“肺虚络瘀”论、“热毒滞络”论、“肺寒络凝”论、其他)、临床研究(古方、自拟方、中成药、六字诀呼吸操、热敏灸)2方面进行了综述,以期为此病的治疗提供有益的参考。 展开更多
关键词 肺痿 特发性肺纤维化 中医药疗法 综述
下载PDF
特发性肺纤维化合并肺动脉高压的发病机制和治疗进展
9
作者 吴常伟 罗祠君 刘锦铭 《同济大学学报(医学版)》 2024年第5期649-655,共7页
特发性肺纤维化的晚期常合并肺动脉高压,病理表现为肺血管重塑、增殖和炎症,肺动脉高压的出现加重原有肺部疾病症状,导致右心衰竭,死亡风险增加、预后差、社会及家庭负担重。特发性肺纤维化合并肺动脉高压目前病因尚不明确、治疗棘手。... 特发性肺纤维化的晚期常合并肺动脉高压,病理表现为肺血管重塑、增殖和炎症,肺动脉高压的出现加重原有肺部疾病症状,导致右心衰竭,死亡风险增加、预后差、社会及家庭负担重。特发性肺纤维化合并肺动脉高压目前病因尚不明确、治疗棘手。本文对特发性肺纤维化合并肺动脉高压的发病机制及治疗进展进行综述,以期为特发性肺纤维化合并肺动脉高压的研究和治疗方案的制定提供新的思路。 展开更多
关键词 特发性肺纤维化 肺动脉高压 发病机制 治疗 进展
下载PDF
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis 被引量:72
10
作者 Jincheng Wang Kaili Hu +4 位作者 Xuanyan Cai Bo Yang Qiaojun He Jiajia Wang Qinjie Weng 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2022年第1期18-32,共15页
Idiopathic pulmonary fibrosis(IPF) is a chronic progressive fibrotic interstitial pneumonia with unknown causes. The incidence rate increases year by year and the prognosis is poor without cure.Recently, phosphatidyli... Idiopathic pulmonary fibrosis(IPF) is a chronic progressive fibrotic interstitial pneumonia with unknown causes. The incidence rate increases year by year and the prognosis is poor without cure.Recently, phosphatidylinositol 3-kinase(PI3 K)/protein kinase B(PKB/AKT) signaling pathway can be considered as a master regulator for IPF. The contribution of the PI3 K/AKT in fibrotic processes is increasingly prominent, with PI3 K/AKT inhibitors currently under clinical evaluation in IPF. Therefore,PI3 K/AKT represents a critical signaling node during fibrogenesis with potential implications for the development of novel anti-fibrotic strategies. This review epitomizes the progress that is being made in understanding the complex interpretation of the cause of IPF, and demonstrates that PI3 K/AKT can directly participate to the greatest extent in the formation of IPF or cooperate with other pathways to promote the development of fibrosis. We further summarize promising PI3 K/AKT inhibitors with IPF treatment benefits, including inhibitors in clinical trials and pre-clinical studies and natural products, and discuss how these inhibitors mitigate fibrotic progression to explore possible potential agents, which will help to develop effective treatment strategies for IPF in the near future. 展开更多
关键词 idiopathic pulmonary fibrosis PI3K/AKT signaling PATHOGENESIS Coagulation cascade Immune activation Fibroblast accumulation Therapeutic target Drug therapy
原文传递
Genetic characterization of a Chinese family with familial idiopathic pulmonary fibrosis 被引量:5
11
作者 ZHANG Xin JIANG Jun +2 位作者 CHEN Wei-jun SU Long-xiang XIE Li-xin 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第11期1945-1951,共7页
Background Idiopathic pulmonary fibrosis (IPF) is a chronic inflammatory interstitial lung disease with an unknown cause. Recent studies have shown that genetic factors play an important role in the pathogenesis of ... Background Idiopathic pulmonary fibrosis (IPF) is a chronic inflammatory interstitial lung disease with an unknown cause. Recent studies have shown that genetic factors play an important role in the pathogenesis of IPF. Methods To explore the genetic background of patients with IPF, a candidate gene approach was employed to screen for mutations in seven genes among members with familial IPF in mainland of China. Results Within six of the candidate genes, a total of 31 point mutations were identified. Among the missense mutations, the SFTPA1 exon 6 CAG〉AAG (GIn238Lys) and SFTPB exon 2 CAC〉CCC (His2Pro) mutations caused changes in the physical and chemical properties of amino acids. Each sequence alteration was identified in sporadic IPF patients, control specimens (pneumonia patients and healthy persons). Genotype frequencies and allele frequencies of codon 238 in exon 6 of SFTPA1 were noted significantly higher in patients with IPF than those in other two control subjects. The computational protein structure prediction by protein homology modeling confirmed differences in three-dimensional structure between mutant SFTPA1 and original SFTPAI. Conclusions Although the functions of the mutant candidate genes vary, these genes may ultimately result in damage to alveolar epithelial cells, initiating the progress of pulmonary fibrosis. In particular, while pathophysiological mechanisms need to be illustrated, the GIn238Lys missense variant of exon 6 in the SFTPA1 may have potential susceptibility in the development of IPF, which was shown in patients with sporadic IPF with a statistically higher frequency. 展开更多
关键词 idiopathic pulmonary fibrosis FAMILIAL interstitial lung disease GENETICS CHINESE
原文传递
LncRNA FEZF1-AS1通过调控EZH2对肺间质细胞增殖、迁移及侵袭的作用 被引量:1
12
作者 王春燕 王萍 +2 位作者 宋龙飞 刘永全 满君 《基础医学与临床》 2024年第1期43-50,共8页
目的研究长链非编码RNA FEZ家族锌指1-反义RNA 1(lncRNA FEZF1-AS1)调控zeste同源物增强子2(EZH2)对肺间质细胞增殖、迁移、侵袭能力及上皮细胞-间质转化(EMT)的影响及其作用机制。方法将人肺腺癌细胞系A549分为对照组(control)和模型组... 目的研究长链非编码RNA FEZ家族锌指1-反义RNA 1(lncRNA FEZF1-AS1)调控zeste同源物增强子2(EZH2)对肺间质细胞增殖、迁移、侵袭能力及上皮细胞-间质转化(EMT)的影响及其作用机制。方法将人肺腺癌细胞系A549分为对照组(control)和模型组[model,用转化生长因子β1(TGF-β1)20 ng/mL作用48 h,诱导成为肺间质细胞]。用Western blot检测细胞中E-钙黏蛋白(E-cadherin)、N-钙黏蛋白(N-cadherin)及波形蛋白(vimentin)的蛋白表达。RT-qPCR检测细胞中lncRNA FEZF1-AS1和EZH2基因表达。转染组细胞分为转染si NC组、si lncRNA FEZF1-AS1+OE vector组和si lncRNA FEZF1-AS1+OE EZH2组。CCK-8法检测细胞增殖、细胞划痕检测细胞迁移、Transwell小室法检测细胞侵袭;用Western blot检测细胞中E-cadherin、N-cadherin、vimentin及EZH2的蛋白表达,用RNA免疫沉淀(RIP)测定FEZF1-AS1与EZH2的直接结合作用。结果与对照组比较,模型组E-cadherin的蛋白表达水平减少(P<0.05);N-cadherin及vimentin的蛋白表达水平升高(P<0.05);与对照组比较,模型组lncRNA FEZF1-AS1与EZH2基因的表达水平明显升高(P<0.05);与si NC组相比,si lncRNA FEZF1-AS1+OE vector组细胞增殖、迁移、侵袭能力降低,E-cadherin蛋白表达升高,N-cadherin、vimentin、EZH2蛋白表达降低(P<0.05);与si lncRNA FEZF1-AS1+OE vector组比较,si lncRNA FEZF1-AS1+OE EZHZ组细胞增殖、侵袭、迁移能力升高,E-cadherin蛋白表达降低,N-cadherin、vimentin、EZH2蛋白表达升高(P<0.05);RIP实验进一步证实了lncRNA FEZF1-AS1与EZH2具有结合作用。结论LncRNA FEZF1-AS1通过调控EZH2促进肺间质细胞增殖、侵袭、转移和EMT过程。 展开更多
关键词 特发性肺间质纤维化 FEZ家族锌指1-反义RNA 1(FEZF1-AS1) 上皮细胞-间充质转化(EMT) zeste基因增强子同源物2(EZH2) 人非小细胞肺癌细胞系A549
下载PDF
LncRNA FEZF1-AS1靶向调控miR-200c-3p对人肺成纤维细胞生物学行为的影响
13
作者 满君 高艳艳 +1 位作者 宋龙飞 高福生 《天津医药》 CAS 2024年第3期231-236,共6页
目的探讨FEZ家族锌指1-反义RNA1(LncRNA FEZF1-AS1)靶向调控miR-200c-3p对人肺成纤维细胞HLF生物学行为的影响。方法采用转化生长因子β1(TGF-β1)诱导HLF向肌成纤维细胞转化,分为空白对照组(Blank组)和造模组(HLF+TGF-β1组),另根据转... 目的探讨FEZ家族锌指1-反义RNA1(LncRNA FEZF1-AS1)靶向调控miR-200c-3p对人肺成纤维细胞HLF生物学行为的影响。方法采用转化生长因子β1(TGF-β1)诱导HLF向肌成纤维细胞转化,分为空白对照组(Blank组)和造模组(HLF+TGF-β1组),另根据转染质粒不同将细胞分为Blank组、TGF-β1+Si LncRNA FEZF1-AS1 NC组和TGF-β1+Si LncRNA FEZF1-AS1组。采用Western blot法检测α-平滑肌肌动蛋白(α-SMA)、Ⅰ型胶原蛋白(CollagenⅠ)和波形蛋白(Vimentin)蛋白的表达。采用实时荧光定量PCR(qRT-PCR)检测LncRNA FEZF1-AS1和miR-200c-3p的表达。采用CCK-8法检测细胞增殖,细胞划痕实验检测迁移能力,Transwell实验检测侵袭能力;采用双萤光素酶实验检测FEZF1-AS1与miR-200c-3p的靶向作用关系。结果与Blank组比较,HLF+TGF-β1组α-SMA、CollagenⅠ、Vimentin蛋白表达及LncRNA FEZF1-AS1表达水平升高,miR-200c-3p表达水平降低(P<0.05);与TGF-β1+Si LncRNA FEZF1-AS1 NC组比较,TGF-β1+Si LncRNA FEZF1-AS1组细胞增殖、迁移、侵袭能力下降,LncRNA FEZF1-AS1表达及α-SMA、CollagenⅠ、Vimentin蛋白表达水平降低,miR-200c-3p表达水平升高(P<0.05);FEZF1-AS1与miR-200c-3p基因序列上存在结合位点。结论LncRNA FEZF1-AS1通过抑制miR-200c-3p促进特发性肺间质纤维化的发生、发展。 展开更多
关键词 特发性肺间质纤维化 肺成纤维细胞 肌成纤维细胞 FEZ家族锌指1-反义RNA1 微小RNA-200c-3p
下载PDF
人工智能在特发性肺纤维化中的研究进展
14
作者 王艳艳 吴华伟(审校) 《国际医学放射学杂志》 2024年第1期48-52,共5页
特发性肺纤维化(IPF)是一种可致死的慢性进行性纤维化间质性肺炎。早期诊断并及时开始抗纤维化治疗是延长IPF病人生存时间的关键。人工智能(AI)技术能够从影像数据中自动学习人眼无法识别的特征,在计算机辅助检测(CAD)系统中的应用可以... 特发性肺纤维化(IPF)是一种可致死的慢性进行性纤维化间质性肺炎。早期诊断并及时开始抗纤维化治疗是延长IPF病人生存时间的关键。人工智能(AI)技术能够从影像数据中自动学习人眼无法识别的特征,在计算机辅助检测(CAD)系统中的应用可以提供决策支持,有助于提高IPF的诊断准确性并预测疾病进展。就AI的相关概念及其在IPF诊断、疾病进展与预后预测以及药物治疗反应评估中的研究现状予以综述。 展开更多
关键词 特发性肺纤维化 间质性肺炎 人工智能 计算机辅助检测 体层摄影术 X线计算机
下载PDF
代谢重编程在特发性肺纤维化发病中的作用
15
作者 段然 李青原 冯同 《基础医学与临床》 CAS 2024年第6期882-886,共5页
肺纤维化是由肺泡上皮反复受损,导致异常的上皮-成纤维细胞转化和肌成纤维细胞产生,进而导致细胞外基质大量积累和间质重塑引起的。与大多数肿瘤细胞类似,肺纤维化过程中也发生了代谢重编程,包括糖、脂、氨基酸代谢等改变,具体表现为糖... 肺纤维化是由肺泡上皮反复受损,导致异常的上皮-成纤维细胞转化和肌成纤维细胞产生,进而导致细胞外基质大量积累和间质重塑引起的。与大多数肿瘤细胞类似,肺纤维化过程中也发生了代谢重编程,包括糖、脂、氨基酸代谢等改变,具体表现为糖酵解的上调、脂肪酸氧化减弱而合成增强、谷氨酰胺分解增加。糖酵解为纤维化形成过程中巨噬细胞、成纤维细胞等的大量增殖提供快速和高效的能量供应,满足其能量需求。活化后的成纤维细胞氨基酸代谢重编程不仅促进了胶原的合成,也在羟脯氨酸合成过程中通过形成ROS加剧了肌成纤维细胞活化进程。 展开更多
关键词 特发性肺纤维化 代谢重编程 糖酵解 靶向治疗
下载PDF
凝血纤溶系统失衡与肺间质纤维化合并呼吸衰竭患者炎性指标相关性分析
16
作者 王莹莹 顾东伟 郑磊 《河北医学》 CAS 2024年第5期844-849,共6页
目的:探讨凝血纤溶系统失衡与肺间质纤维化(Idiopathic pulmonary fibrosis,IPF)合并呼吸衰竭(Respiratory failure,RF)患者炎性指标相关性。方法:选择我院2020年10月至2023年12月IPF患者98例,依据是否合并RF分为RF组(n=42)与无RF组(n=... 目的:探讨凝血纤溶系统失衡与肺间质纤维化(Idiopathic pulmonary fibrosis,IPF)合并呼吸衰竭(Respiratory failure,RF)患者炎性指标相关性。方法:选择我院2020年10月至2023年12月IPF患者98例,依据是否合并RF分为RF组(n=42)与无RF组(n=56)。采用全自动凝血分析仪测定活化部分凝血活酶时间(activated partial thromboplastin time,APTT)、凝血酶时间(thrombin time,TT)、凝血酶原时间(prothrombin time,PT)和纤维蛋白原(fibrinogen,FIB)水平,免疫比浊法测定D-二聚体(D-Dimer,D-D)水平;全自动血细胞分析仪测定中性粒细胞百分比(Neutrophil percentage,NEUT)和白细胞计数(white blood cell count,WBC),酶联免疫吸附法测定C反应蛋白(C-reactive protein,CRP)水平,放射免疫分析法测定降钙素原(Procalcitonin,PCT)水平。比较两组凝血纤溶指标和炎性指标水平变化;采用Pearson分析凝血纤溶指标与炎性指标相关性;分析凝血纤溶指标和炎性指标与IPF合并RF关系。结果:RF组APTT、TT和PT低于无RF组,而FIB和D-D高于无RF组,差异均有统计学意义(P<0.05)。RF组NEUT、WBC、CRP和PCT水平高于无RF组,差异均有统计学意义(P<0.05)。经Pearson分析,APTT、TT和PT与NEUT、WBC、CRP和PCT呈线性负相关,而FIB和D-D与NEUT、WBC、CRP和PCT呈线性正相关(P<0.05)。APTT、TT、PT、FIB、D-D、NEUT、WBC、CRP和PCT为影响IPF合并RF危险因素。结论:IPF合并RF患者存在凝血纤溶系统失衡和炎性反应,且凝血纤溶系统失衡与炎性指标变化密切相关,值得临床借鉴。 展开更多
关键词 凝血纤溶系统 肺间质纤维化 呼吸衰竭 炎性指标
下载PDF
无创呼吸机联合吡非尼酮对特发性肺间质纤维化的临床疗效
17
作者 齐荣艳 牟艳 《当代医学》 2024年第1期157-160,共4页
目的分析无创呼吸机联合吡非尼酮对特发性肺间质纤维化(IPF)的临床疗效。方法选取2019年12月至2020年12月临清市人民医院收治的120例IPF患者作为研究对象,按照随机数字表法分为研究组与对照组,每组60例。对照组采用无创呼吸机治疗,研究... 目的分析无创呼吸机联合吡非尼酮对特发性肺间质纤维化(IPF)的临床疗效。方法选取2019年12月至2020年12月临清市人民医院收治的120例IPF患者作为研究对象,按照随机数字表法分为研究组与对照组,每组60例。对照组采用无创呼吸机治疗,研究组在对照组基础上联用吡非尼酮,比较两组临床疗效、肺功能指标[第1秒用力呼气容积(FEV1)及第1秒用力呼气容积占预计值的百分比(FEV1/FVC%)]、血流动力学指标[平均动脉压(MAP)、心率(HR)]及血清炎症因子[肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)]水平。结果研究组治疗总有效率为96.67%,高于对照组的85.00%,差异有统计学意义(P<0.05);治疗后,两组FEV1、FEV1/FVC%均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组MAP、HR均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组TNF-ɑ、IL-6水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。结论无创呼吸机联合吡非尼酮治疗IPF的疗效显著,能有效缓解患者心肺功能指标,改善血流动力学指标和炎症因子水平,值得临床推广应用。 展开更多
关键词 无创呼吸机 吡非尼酮 特发性肺间质纤维化 心肺功能
下载PDF
吡非尼酮联合乙酰半胱氨酸治疗特发性肺间质纤维化的疗效评价
18
作者 刘贞祥 王军 崔晓靖 《中外医疗》 2024年第3期120-123,共4页
目的探究吡非尼酮联合乙酰半胱氨酸治疗特发性肺间质纤维化的疗效。方法回顾性选取2018年1月—2023年1月寿光市中医医院100例特发性肺间质纤维化患者的临床资料,按照用药方案不同分为两组,每组50例。对照组实施吡非尼酮治疗,观察组实施... 目的探究吡非尼酮联合乙酰半胱氨酸治疗特发性肺间质纤维化的疗效。方法回顾性选取2018年1月—2023年1月寿光市中医医院100例特发性肺间质纤维化患者的临床资料,按照用药方案不同分为两组,每组50例。对照组实施吡非尼酮治疗,观察组实施吡非尼酮联合乙酰半胱氨酸治疗。比较两组患者治疗效果。结果观察组治疗有效率(96.00%)高于对照组的80.00%,差异有统计学意义(χ^(2)=6.060,P<0.05)。观察组肺部功能指标水平明显高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。观察组肺纤维化指标水平明显低于对照组,差异有统计学意义(P<0.05)。结论吡非尼酮、乙酰半胱氨酸联合的方法治疗特发性肺间质纤维化患者,可改善患者临床症状,显著提升治疗效果。 展开更多
关键词 吡非尼酮 乙酰半胱氨酸 特发性 肺间质纤维化
下载PDF
复方甘草口服液联合泼尼松治疗特发性肺间质纤维化急性加重期患者的疗效及安全性研究
19
作者 刘丽 张明 +2 位作者 任建兵 米奇珍 闫有鹏 《广州医药》 2024年第10期1177-1182,共6页
目的探讨复方甘草口服液联合泼尼松治疗特发性肺间质纤维化急性加重期患者的疗效。方法选取张掖市第二人民医院2020年1月—2023年10月收治的128例特发性肺间质纤维化急性加重期患者,应用随机数字表法分为两组,每组各64例。对照组采取泼... 目的探讨复方甘草口服液联合泼尼松治疗特发性肺间质纤维化急性加重期患者的疗效。方法选取张掖市第二人民医院2020年1月—2023年10月收治的128例特发性肺间质纤维化急性加重期患者,应用随机数字表法分为两组,每组各64例。对照组采取泼尼松治疗,观察组采取复方甘草口服液联合泼尼松治疗。对比其临床疗效,治疗前后血清肺纤维化指标及炎症因子水平,最后对比其不良反应发生率。结果观察组总有效率93.75%,高于对照组的79.69%(χ^(2)=5.490,P=0.019);治疗前两组层黏连蛋白(LN)、Ⅲ型前胶原肽(PC-Ⅲ)、透明质酸(HA)对比差异无统计学意义(P>0.05),治疗后两组患者LN、PC-Ⅲ、HA均降低,观察组[(89.25±7.61)μg/L;(68.33±7.68)mg/L;(81.53±8.54)μg/L]低于对照组[(96.17±8.34)μg/L;(75.68±8.25)mg/L;(95.68±9.25)μg/L],对比差异有统计学意义(t_(1)=4.903,P_(1)<0.001;t_(2)=5.217,P_(2)<0.001;t_(3)=8.992,P_(3)<0.001);治疗前两组患者肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)、IL-10、转化生长因子(TGF-β1)对比差异无统计学意义(P>0.05),治疗后两组TNF-α、IL-4、IL-10、TGF-β1水平降低,观察组[(61.94±8.24)ng/L;(4.43±1.17)ng/mL;(65.49±13.24)g/L;(114.73±13.12)pg/mL]低于对照组[(75.52±9.43)ng/L;(6.31±1.28)ng/mL;(79.27±9.38)g/L;(147.76±15.46)pg/mL],对比差异有统计学意义(t_(1)=8.675,P1<0.001;t_(2)=8.673,P_(2)<0.001;t_(3)=6.794,P_(3)<0.001;t_(4)=13.032,P4<0.001);两组不良反应发生率对比差异无统计学意义(7.81%vs 6.25%,χ^(2)=0.120,P=0.730)。结论复方甘草口服液联合泼尼松治疗特发性肺间质纤维化急性加重期疗效显著,可辅助延缓患者肺纤维化发展进程,减轻机体炎症反应,安全性较高。 展开更多
关键词 复方甘草口服液 泼尼松 特发性肺间质纤维化 急性加重期 不良反应 炎症因子
下载PDF
成人特发性肺纤维化(更新)和进行性肺纤维化临床实践指南(2022版)解读 被引量:11
20
作者 于娜 周家为 +2 位作者 李霞 张婷 刘紫艳 《中国现代医学杂志》 CAS 北大核心 2023年第14期1-8,共8页
2022年5月美国胸科学会(ATS)、欧洲呼吸学会(ERS)、日本呼吸学会(JRS)、拉丁美洲胸科协会(ALAT)四大学会联合发表成人特发性肺纤维化(IPF)(更新)和进行性肺纤维化(PPF)临床实践指南,该指南对2018版ATS、ERS、JRSALAT发布的IPF临床实践... 2022年5月美国胸科学会(ATS)、欧洲呼吸学会(ERS)、日本呼吸学会(JRS)、拉丁美洲胸科协会(ALAT)四大学会联合发表成人特发性肺纤维化(IPF)(更新)和进行性肺纤维化(PPF)临床实践指南,该指南对2018版ATS、ERS、JRSALAT发布的IPF临床实践指南进行部分更新,并提出了PPF的定义。在2022版成人IPF和PPF临床实践指南发布近1周年之际,该文重新审视并解读指南变更对间质性肺疾病临床研究及实践的影响,进一步探讨未来IPF、PPF领域可能的发展方向及热点。 展开更多
关键词 间质性肺疾病 特发性肺纤维化 进行性肺纤维化 指南
下载PDF
上一页 1 2 13 下一页 到第
使用帮助 返回顶部